Cloud3 Ventures Inc. announced it will change its corporate name to Aeon Strategies Ltd. to better align with its long-term vision and investment strategy. The company's trading symbol will also change from CLDV to AEON on the Canadian Securities Exchange starting October 9, 2026. The company remains focused on investing in high-potential companies across various sectors to maximize returns. This rebranding reflects a strategic shift and aims to better represent the company's future direction.
Cloud3 Ventures Inc.'s corporate name change to Aeon Strategies Ltd. is presented here with Financials-sector market data from Pluang as of Oct 07, 2026 04:22 WIB. Of 85 priced US Financials stocks, 46 rose and 37 fell. MasterCard Inc. (MA) rose 2.45% to USD 565.81 with 94% sell orders and a typical hold time of 134 days, contrasting with Gemini Space Station Inc. (GEMI) which fell 2.10% to USD 4.67 and has a much shorter typical hold time of 14 days. Nasdaq Inc. (NDAQ) also rose 2.13% to USD 92.25 with a more balanced order activity of 62% sell and 38% buy, and a hold time of 125 days.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
U.S. spot Solana ETFs experienced $3.7 million in net outflows on October 6, marking the second consecutive day of withdrawals. The Grayscale Solana Trust was the main contributor to this decline, while six other funds showed no net flow. Although th...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
